Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The mortality rate may reach 80-90% in the absence of liver transplantation. Liver injury is considered to be mainly immune mediated with augmentation of cytolytic pathways of infected hepatocytes. For that, it is suggested that corticosteroids modulate the activity of the disease by suppressing the immune system.
Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The mortality rate may reach 80-90% in the absence of liver transplantation. FHF is the clinical manifestation of liver cell death of a critical degree with insufficient hepatocellular regeneration and characterized by coagulopathy with or without hepatic encephalopathy. Liver injury is considered to be mainly immune mediated with augmentation of cytolytic pathways of infected hepatocytes. For that, it was suggested that corticosteroids modulate the activity of the disease by suppressing the immune system.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Oral administration of 1 mg/Kg/day
Intravenous injection of 0.8 mg/kg/day
National Liver Institute
Menoufia, Menoufia, Egypt
Side effect 1 Number of patients with anaphylaxis
Number of patients with anaphylaxis
Time frame: 2 months
Side effect 2 Number of patients with angioedema
Number of patients with angioedema
Time frame: 2 months
Side effect 3 Number of patients with cardiac arrest
Number of patients with cardiac arrest
Time frame: 2 months
Side effect 4 Number of patients with arrhythmias
Number of patients with arrhythmias
Time frame: 2 months
Side effect 5 Number of patients with circulatory collapse
Number of patients with circulatory collapse
Time frame: 2 months
Side effect 6 Number of patients with congestive heart failure
Number of patients with congestive heart failure
Time frame: 2 months
Side effect 7 Number of patients with pulmonary edema
Number of patients with pulmonary edema
Time frame: 2 months
Side effect 8 Number of patients with pancreatitis
Number of patients with pancreatitis
Time frame: 2 months
Efficacy 1 Number of survivors
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
number of living patients
Time frame: 2 months
Efficacy 2 Number of deaths
number of died patients
Time frame: 2 months
Efficacy 3 serum prothrombin time
serum prothrombin time
Time frame: 72 hour
Efficacy 3 grade of encephalopathy
grade of encephalopathy
Time frame: 72 hour
Efficacy 4 duration of encephalopathy
duration of encephalopathy
Time frame: 2 months